Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Harvard Business School
McKesson
AstraZeneca
Johnson and Johnson

Last Updated: May 19, 2022

VIBATIV Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

DrugPatentWatch® Generic Entry Outlook for Vibativ

Vibativ was eligible for patent challenges on September 11, 2013.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 1, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for VIBATIV
Drug patent expirations by year for VIBATIV
Drug Prices for VIBATIV

See drug prices for VIBATIV

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VIBATIV
Generic Entry Date for VIBATIV*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIBATIV

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Theravance Biopharma, US, Inc.Phase 4
Joseph L. Kuti, PharmDPhase 4
Cumberland Pharmaceuticals, Inc.Phase 4

See all VIBATIV clinical trials

Pharmacology for VIBATIV

US Patents and Regulatory Information for VIBATIV

VIBATIV is protected by three US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIBATIV is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VIBATIV

Glycopeptide phosphonate derivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD FOR TREATING BACTERIAL INFECTION

Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Hydrochloride salts of a glycopeptide phosphonate derivative
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-001 Sep 11, 2009 DISCN Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-001 Sep 11, 2009 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-001 Sep 11, 2009 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Cumberland Pharms VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110-002 Sep 11, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIBATIV

International Patents for VIBATIV

When does loss-of-exclusivity occur for VIBATIV?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 04285924
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0415853
Estimated Expiration: See Plans and Pricing

Canada

Patent: 43009
Estimated Expiration: See Plans and Pricing

Patent: 26967
Estimated Expiration: See Plans and Pricing

China

Patent: 71253
Estimated Expiration: See Plans and Pricing

Patent: 0417661
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 13773
Estimated Expiration: See Plans and Pricing

Patent: 15276
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 78201
Estimated Expiration: See Plans and Pricing

Patent: 95251
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 78201
Estimated Expiration: See Plans and Pricing

Patent: 95251
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 93516
Estimated Expiration: See Plans and Pricing

Patent: 71030
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 26769
Estimated Expiration: See Plans and Pricing

Japan

Patent: 69478
Estimated Expiration: See Plans and Pricing

Patent: 07534630
Estimated Expiration: See Plans and Pricing

Patent: 11016820
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 06004336
Estimated Expiration: See Plans and Pricing

Poland

Patent: 78201
Estimated Expiration: See Plans and Pricing

Patent: 95251
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 78201
Estimated Expiration: See Plans and Pricing

Patent: 95251
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 78201
Estimated Expiration: See Plans and Pricing

Patent: 95251
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1166250
Estimated Expiration: See Plans and Pricing

Patent: 060094082
Estimated Expiration: See Plans and Pricing

Patent: 120037025
Estimated Expiration: See Plans and Pricing

Spain

Patent: 00483
Estimated Expiration: See Plans and Pricing

Patent: 77268
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 42312
Estimated Expiration: See Plans and Pricing

Patent: 0528473
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIBATIV around the world.

Country Patent Number Title Estimated Expiration
Spain 2271012 See Plans and Pricing
Slovenia 1292612 See Plans and Pricing
Mexico PA02012745 DERIVADOS DE FOSFONATOS DE GLICOPEPTIDOS. (GLYCOPEPTIDE PHOSPHONATE DERIVATIVES.) See Plans and Pricing
Canada 2407994 PROCEDE D'ALKYLATION REDUCTRICE (REDUCTIVE ALKYLATION PROCESS) See Plans and Pricing
Poland 359419 See Plans and Pricing
Brazil 0110530 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VIBATIV

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1292612 C 2012 002 Romania See Plans and Pricing PRODUCT NAME: TELAVANCIN SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIAINCLUZAND CLORHIDRAT DE TELAVANCIN; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/705/001, RO EU/1/11/705/002; DATE OF NATIONAL AUTHORISATION: 20110902; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/705/001, EU/1/11/705/002; DATE OF FIRST AUTHORISATION IN EEA: 20110902
1292612 91908 Luxembourg See Plans and Pricing 91908, EXPIRES: 20260501
1292612 1190036-2 Sweden See Plans and Pricing PRODUCT NAME: TELAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV INNEFATTANDE TELAVANCINHYDROKLORID; REG. NO/DATE: EU/1/11/705/001 20110902
1292612 CA 2011 00033 Denmark See Plans and Pricing PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID
1292612 417 Finland See Plans and Pricing
1292612 122011100062 Germany See Plans and Pricing PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Johnson and Johnson
Medtronic
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.